DEUTSCHE BANK AG\ - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 110 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2019. The put-call ratio across all filers is 2.28 and the average weighting 0.7%.

Quarter-by-quarter ownership
DEUTSCHE BANK AG\ ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q3 2023$242,805
-2.2%
28,135
+17.2%
0.00%
Q2 2023$248,369
-52.2%
23,997
-49.9%
0.00%
Q1 2023$519,585
+10.4%
47,888
+14.1%
0.00%
Q4 2022$470,780
+54.4%
41,959
+39.6%
0.00%
Q3 2022$305,000
-17.1%
30,063
-25.9%
0.00%
Q2 2022$368,000
-9.4%
40,574
-4.2%
0.00%
Q1 2022$406,000
-19.9%
42,366
-7.6%
0.00%
Q4 2021$507,000
+70.7%
45,869
+14.4%
0.00%
Q3 2021$297,000
-45.1%
40,101
+7.7%
0.00%
Q2 2021$541,000
-87.0%
37,238
-81.8%
0.00%
-100.0%
Q1 2021$4,170,000
+9.2%
204,286
-5.0%
0.00%0.0%
Q4 2020$3,819,000
-1.3%
214,971
-17.9%
0.00%
-33.3%
Q3 2020$3,870,000
-61.8%
261,742
-45.7%
0.00%
-62.5%
Q2 2020$10,118,000
-8.1%
482,021
+1.2%
0.01%
-20.0%
Q1 2020$11,010,000
+929.0%
476,386
+1049.4%
0.01%
+900.0%
Q4 2019$1,070,000
+328.0%
41,448
+220.6%
0.00%
Q3 2019$250,000
-43.9%
12,929
-52.9%
0.00%
Q2 2019$446,000
-65.0%
27,443
-51.3%
0.00%
-100.0%
Q1 2019$1,276,000
-4.6%
56,394
+7.6%
0.00%0.0%
Q4 2018$1,338,000
-88.7%
52,394
-85.5%
0.00%
-66.7%
Q3 2018$11,830,000
+137.5%
362,203
+64.8%
0.00%
+200.0%
Q2 2018$4,982,000
+88.1%
219,747
+101.1%
0.00%0.0%
Q1 2018$2,648,000
-12.6%
109,295
+0.5%
0.00%
-50.0%
Q4 2017$3,031,000
+48.7%
108,750
+82.4%
0.00%
+100.0%
Q3 2017$2,038,000
-12.1%
59,613
+2.3%
0.00%
-50.0%
Q2 2017$2,318,000
+236.9%
58,276
+211.3%
0.00%
+100.0%
Q1 2017$688,000
-72.5%
18,718
-76.2%
0.00%
-50.0%
Q4 2016$2,506,000
+44.4%
78,707
+64.2%
0.00%
+100.0%
Q3 2016$1,735,000
+61.2%
47,939
+0.7%
0.00%0.0%
Q2 2016$1,076,000
+42.3%
47,610
+17.9%
0.00%0.0%
Q1 2016$756,000
+61.9%
40,392
+40.6%
0.00%
Q4 2015$467,000
+96.2%
28,725
+31.4%
0.00%
Q3 2015$238,000
-92.4%
21,862
-90.9%
0.00%
-100.0%
Q2 2015$3,143,000
+841.0%
241,553
+1143.8%
0.00%
Q1 2015$334,000
-91.9%
19,420
-93.0%
0.00%
-100.0%
Q4 2014$4,148,000
+79.8%
278,209
+177.8%
0.00%
+200.0%
Q3 2014$2,307,000
-46.0%
100,141
-25.3%
0.00%
-66.7%
Q2 2014$4,269,000133,9920.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q4 2019
NameSharesValueWeighting ↓
Woodford Investment Management Ltd 10,898,879$264,297,00023.51%
Foundation Asset Management, LP 399,537$9,689,0003.59%
Cormorant Asset Management, LP 1,300,000$31,525,0002.35%
Baupost Group 9,309,168$225,747,0002.18%
Old West Investment Management, LLC 109,320$2,651,0001.53%
SENZAR ASSET MANAGEMENT, LLC 187,856$4,555,0001.44%
Chescapmanager LLC 350,631$8,503,0001.27%
Virtus ETF Advisers LLC 32,989$800,0000.69%
Rock Springs Capital Management LP 652,600$15,826,0000.68%
NJ State Employees Deferred Compensation Plan 34,142$828,0000.15%
View complete list of THERAVANCE BIOPHARMA INC shareholders